Navigation Links
Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/3/2009

PALO ALTO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that company management will present a corporate overview at two upcoming investor conferences.

Robert M. Myers, President of Jazz Pharmaceuticals, will speak at the Rodman & Renshaw Annual Global Investment Conference on Thursday, September 10, 2009 at 3:15 p.m. EDT at the Palace Hotel in New York City.

Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals, will speak at the NewsMakers in the Biotech Industry Conference on Wednesday, September 16, 2009 at 9:00 a.m. EDT, at the Millennium Broadway Hotel in New York City.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information please see www.jazzpharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
3. Steven Holtzman Joins Satori Pharmaceuticals Board of Directors
4. Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
5. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010
6. Isis Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
7. Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism
8. DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
9. Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
10. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
11. Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... a national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel ... also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: